Given that perturbed vesicular function is a feature of major neurodegenerative diseases, inducing SYNGR3 expression by NURR1 activators may be a potential therapeutic target to attenuate synaptic dysfunction in PD. This evidence concerns the gene NR4A2 and neurodegenerative disease.